+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha Emitters - Global Market Trajectory & Analytics

  • ID: 5139395
  • Report
  • April 2021
  • Region: Global
  • 113 Pages
  • Global Industry Analysts, Inc
Global Alpha Emitters Market to Reach $5.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Alpha Emitters estimated at US$672.3 Million in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 34.1% over the analysis period 2020-2027. Melanoma, one of the segments analyzed in the report, is projected to record a 35.1% CAGR and reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Pancreatic Cancer segment is readjusted to a revised 37.1% CAGR for the next 7-year period.



The U.S. Market is Estimated at $202.5 Million, While China is Forecast to Grow at 33% CAGR

The Alpha Emitters market in the U.S. is estimated at US$202.5 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$885.2 Million by the year 2027 trailing a CAGR of 33% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 30.8% and 29.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 23.9% CAGR.

Ovarian Cancer Segment to Record 32.8% CAGR

In the global Ovarian Cancer segment, USA, Canada, Japan, China and Europe will drive the 32.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$112 Million in the year 2020 will reach a projected size of US$813.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$628.7 Million by the year 2027.

Select Competitors (Total 41 Featured):
  • Actinium Pharmaceuticals, Inc.
  • Alpha Tau Medical
  • Bayer AG
  • Fusion Pharma
  • IBA Group
  • IBA Radiopharma Solutions
  • Lantheus Medical Imaging, Inc.
  • NTP Radiosotopes SOC Ltd.
  • RadioMedix, Inc.
  • Siemens Healthineers
  • Telix Pharmaceuticals Ltd.
  • Triad Isotopes, Inc.
Frequently Asked Questions about the Global Market for Alpha Emitters

What is the estimated value of the Global Market for Alpha Emitters?

The Global Market for Alpha Emitters was estimated to be valued at $672.3 Million in 2020.

What is the growth rate of the Global Market for Alpha Emitters?

The growth rate of the Global Market for Alpha Emitters is 33.9%, with an estimated value of $5200.0 Million by 2027.

What is the forecasted size of the Global Market for Alpha Emitters?

The Global Market for Alpha Emitters is estimated to be worth $5200.0 Million by 2027.
Note: Product cover images may vary from those shown

I. METHODOLOGY
II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Alpha Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Bone Metastasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Bone Metastasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Other Medical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Other Medical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS
  • Table 13: USA Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 14: USA 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 15: Canada Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 16: Canada 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 17: Japan Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 18: Japan 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 19: China Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: China 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 21: Europe Current & Future Analysis for Alpha Emitters by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 22: Europe 7-Year Perspective for Alpha Emitters by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 23: Europe Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 24: Europe 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 25: France Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: France 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 27: Germany Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 28: Germany 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 29: Italy Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 30: Italy 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 31: UK Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: UK 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 33: Rest of Europe Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 34: Rest of Europe 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 35: Asia-Pacific Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 36: Asia-Pacific 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027
  • Table 37: Rest of World Current & Future Analysis for Alpha Emitters by Medical Application - Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: Rest of World 7-Year Perspective for Alpha Emitters by Medical Application - Percentage Breakdown of Value Sales for Melanoma, Pancreatic Cancer, Ovarian Cancer, Bone Metastasis and Other Medical Applications for the Years 2020 & 2027

IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown